<DOC>
	<DOCNO>NCT02275598</DOCNO>
	<brief_summary>The purpose study assess efficacy two three-weekly 1.8 mg/kg Brentuximab vedotin administration untreated patient Hodgkin Lymphoma ( HL ) .</brief_summary>
	<brief_title>Brentuximab Vedotin Followed ABVD Patients With Previously Untreated Hodgkin Lymphoma</brief_title>
	<detailed_description>This multicenter pilot phase II trial assess 2 administration Brentuximab vedotin follow PET scan subsequent standard treatment ABVD ± Radiotherapy . 12 patient defined inclusion exclusion criterion enrol one year . All subject follow disease evaluation every 3 month one year end therapy disease progression , death , initiation alternative therapy , withdrawal consent , end study . For study procedure patient assign Unique Subject Identifier ( SID ) number use identify subject screen process throughout study participation . A master log maintain consented subject document screen failure ( i.e . subject consent meet study eligibility criterion ) . Study record case report form ( CRFs ) may maintain electronically require security confidentiality paper . Clinical information release without write permission subject/legal representative , except specify informed consent form</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Previouslyuntreated patient classical Hodgkin Lymphoma accord World Health Organisation ( WHO ) classification Histologically confirm CD30+ HL Stage IA , IIA , IIIA Absence bulky disease FDGPET baseline Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 Life expectancy &gt; 6 month . Age 1870 year . Patients must available periodic blood sampling , studyrelated assessment , management toxicity treat institution . Females childbearing potential must negative pregnancy test result within three day enrollment . All patient must agree use effective contraceptive method ( one male two female ) course study 6 month follow end full treatment ( Brentuximab vedotin + ABVD +/ Radiotherapy ) . Written informed consent . Required baseline laboratory data : Absolute neutrophil count ≥ 1000/μl Platelet count ≥ 50.000/ μl Serum bilirubin ≤ 1.5 time ULN Serum creatinine ≤ 1.5 time ULN Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 time ULN Peripheral neuropathy &gt; Grade 1 Histologic diagnosis different Hodgkin Lymphoma Compressive symptom Patients previously treat antiCD30 antibody Known human immunodeficiency virus ( HIV ) positive Known hepatitis B surface antigenpositive , know suspected infection active hepatitis C Patients sign symptom progressive multifocal leukoencephalopathy ( PML ) Patients know cerebral/meningeal disease .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>